Breaking Down Cathay Biotech Inc. Financial Health: Key Insights for Investors

Dive into Cathay Biotech Inc. (688065.SS) with hard numbers that matter: the company posted an operating income of 2.956 billion yuan in 2024 alongside a trailing twelve months revenue of 3.29 billion yuan (TTM as of Dec 22, 2025) reflecting an 18.96% YoY rise, driven in large part by the long-chain dicarboxylic acid series which contributed 2.67 billion yuan in 2024 at a 39.71% gross margin; profitability metrics show net profit attributable to the parent of 487 million yuan in 2024 (up 32.80%) with a net profit margin around 16.5% and EPS of 0.84 yuan, while cash and capitalization tell another story-total cash of 10.80 billion yuan as of Mar 31, 2025 and a market capitalization of 34.82 billion yuan as of Dec 22, 2025-set against valuation multiples including a TTM P/E of 52.64, P/S of 10.36 and EV/EBITDA of 30.48, recent capital moves such as the March 2025 private placement raising 5.93 billion yuan for expansion, and strategic growth initiatives like the Feb 2025 joint venture with CATL and Kalai Composites to commercialize bio-based polyamide composites for battery and transport applications-read on to explore revenue mix (domestic 1.864 billion yuan; overseas 955 million yuan in 2024), Q1 2025 net income of 137 million yuan (up 30.11% YoY), and the liquidity, solvency, valuation and risk metrics investors should weigh.

Cathay Biotech Inc. (688065.SS) - Revenue Analysis

• 2024 operating income: 2.956 billion yuan (+39.84% YoY)
• TTM revenue (as of 2025-12-22): 3.29 billion yuan (+18.96% YoY)
• Market cap (2025-12-22): 34.82 billion yuan

• 2024 revenue from long-chain dicarboxylic acids: 2.67 billion yuan (+39.94% YoY)
• Gross margin for this series in 2024: 39.71%

• Domestic revenue (2024): 1.864 billion yuan (+35.75% YoY)
• Overseas revenue (2024): 955 million yuan (+37.63% YoY)

Cathay Biotech Inc. (688065.SS) - Profitability Metrics

Key profitability indicators for Cathay Biotech Inc. in 2024 highlight notable growth in profitability and efficient operational control across the income statement and asset base. The following figures summarize core metrics investors commonly track.

• Net profit attributable to parent: ¥487 million (2024), +32.80% year-over-year
• Net profit margin: ~16.5% (2024)
• Basic earnings per share (EPS): ¥0.84 (2024)
• Weighted average return on equity (ROE): 4.33% (2024)
• Trailing twelve months (TTM) return on assets (ROA): 1.19%
• Operating margin: 18.45% (2024)

Key drivers behind these figures include improved gross-to-operating conversion and a combination of revenue growth and disciplined expense management, which together lifted margins and EPS while producing a meaningful uptick in net profit. For contextual corporate guidance, see Mission Statement, Vision, & Core Values (2026) of Cathay Biotech Inc.

Cathay Biotech Inc. (688065.SS) Debt vs. Equity Structure

Key capital events and structure indicators for Cathay Biotech Inc. (688065.SS) focused on recent equity issuance and its implications for leverage and funding of expansion.

• Private placement (March 2025): 137,911,755 A shares issued at ¥42.97 per share, raising ¥5.93 billion.
• Registered capital after issuance: ¥721,289,794.
• Market capitalization (as of 22 Dec 2025): ¥34.82 billion.
• Issuance did not change the company's controlling shareholder.
• Proceeds earmarked for capital‑intensive expansion projects.
• Reported debt-to-equity ratio as of 22 Dec 2025: not specified in available sources.

Implications for financial positioning:

• Equity infusion increased shareholders' funds by ¥5.93 billion, improving capacity to fund capital expenditures without immediate additional debt.
• Without a disclosed debt-to-equity ratio, leverage assessment requires reviewing the latest balance sheet for total liabilities; however, the sizeable market cap (¥34.82 billion) versus capital raised suggests equity financing remains a meaningful portion of enterprise value.
• Retention of controlling shareholder reduces governance risk associated with ownership change while enabling management to deploy proceeds toward expansion.

For more background on company structure and operations, see: Cathay Biotech Inc.: History, Ownership, Mission, How It Works & Makes Money

Cathay Biotech Inc. (688065.SS) - Liquidity and Solvency

• Market capitalization (as of 2025-12-22): 34.82 billion yuan.
• Total cash (as of 2025-03-31): 10.80 billion yuan.
• Funds raised in March 2025: earmarked to support capital-intensive expansion plans.
• Issuance effect: did not change the company's controlling shareholder.
• Current ratio & quick ratio: not specified in available sources.
• Debt-to-equity ratio (as of 2025-12-22): not specified in available sources.

• The 10.80 billion yuan cash balance provides near-term liquidity to fund operations and expansion, reducing immediate refinancing needs.
• Without disclosed current/quick ratios or debt-to-equity data, assessment of working-capital adequacy and leverage requires caution or further disclosure requests.
• Capital raises in March 2025 bolster expansion without diluting control, which may indicate strategic alignment between management and shareholders.

Cathay Biotech Inc. (688065.SS) - Valuation Analysis

• Premium growth expectation: TTM P/E of 52.64 and forward P/E of 53.09 signal the market is pricing sustained earnings expansion rather than mean reversion.
• Revenue valuation: P/S of 10.36 and EV/Revenue of 7.37 indicate revenue is being valued at a multiple consistent with high-growth biotech franchises.
• Profitability vs. enterprise value: EV/EBITDA at 30.48 is materially above industrial norms, implying either low current EBITDA margins or aggressive future margin improvement priced in.
• Balance sheet premium: P/B at 2.47 shows investors accept paying more than book value, often for intangible assets, IP, pipelines or R&D potential.

• Growth assumptions embedded in these multiples - small changes in revenue or EPS forecasts materially alter valuation attractiveness.
• Pipeline and regulatory risk - biotech valuations commonly hinge on trial readouts and approvals that can rapidly re-rate multiples.
• Capital structure and cash runway - enterprise multiples (EV/Rev, EV/EBITDA) incorporate debt and cash; understanding current cash burn and financing needs is critical.

Cathay Biotech Inc. (688065.SS) Risk Factors

Investors assessing Cathay Biotech Inc. (688065.SS) should weigh several specific risk considerations tied to liquidity, capital structure transparency, and recent fundraising activities that support capital-intensive expansion.

• Market capitalization: 34.82 billion yuan (as of December 22, 2025).
• Total cash on hand: 10.80 billion yuan (as of March 31, 2025).
• Funds raised in March 2025: designated to support capital-intensive expansion plans.
• Equity issuance impact: the March 2025 issuance did not change the company's controlling shareholder.
• Key ratios not specified in available sources: debt-to-equity ratio (as of December 22, 2025), current ratio, quick ratio.

Liquidity and capital deployment risk: while the company reported substantial cash (10.80 billion yuan) and raised funds in March 2025 to finance expansion, investors should consider execution risk for capital-intensive projects and potential cash burn profiles.

• Funding concentration risk: reliance on large equity or debt raises for expansion could dilute returns or increase leverage if cash needs exceed projections.
• Transparency risk: absence of publicly available liquidity and leverage ratios (debt-to-equity, current ratio, quick ratio) complicates precise assessment of solvency and short-term obligations.
• Operational execution risk: converting raised capital into productive assets and revenue growth for capital-intensive biotech operations entails regulatory, R&D, and commercial milestones that carry uncertainty.
• Shareholder control risk: although the March 2025 issuance preserved the controlling shareholder, future capital raises could alter governance dynamics.

For context on the company's strategic orientation and guiding principles, see: Mission Statement, Vision, & Core Values (2026) of Cathay Biotech Inc.

Cathay Biotech Inc. (688065.SS) - Growth Opportunities

• February 2025: joint venture established with CATL and Kalai Composites to commercialize bio-based polyamide composites.
• JV focus areas: R&D and production of bio-based composite materials for battery shells, energy storage boxes, and transportation components.
• March 2025 capital raise: proceeds earmarked for capital-intensive expansion (production capacity, pilot lines, and scale-up).
• Issuance outcome: no change to the company's controlling shareholder.
• Liquidity as of March 31, 2025: total cash of 10.80 billion yuan to support near-term capex and JV commitments.

• Commercial synergies: partnership with CATL provides direct pathway into EV battery supply chains and large-scale demand for composite battery housings.
• Financial runway: 10.80 billion yuan in cash plus March 2025 proceeds reduce execution risk for capacity build-out and pilot commercialization.
• Market valuation: 34.82 billion yuan market cap (Dec 22, 2025) positions Cathay Biotech as a significant player within specialty materials and biotech-enabled polymers.
• Execution risks: capital intensity of composite production, scale-up timelines, and technology validation in automotive-grade applications.